VIDEO: Terlipressin safe, effective for esophageal bleeding, liver cirrhosis
Click Here to Manage Email Alerts
LAS VEGAS — In this video exclusive, Kevin Moore, MD, discussed a study assessing real-world outcomes in patients with esophageal variceal hemorrhage and liver cirrhosis treated with terlipressin.
The results were presented at the ACG Annual Scientific Meeting.
Moore, professor of hepatology at the University College London’s Institute of Liver and Digestive Health in London, noted among the 195 patients included in the study, about 70% had alcohol-related cirrhosis. He said about 98.5% of patients were treated with terlipressin monotherapy.
“The overall survival was excellent with 70% 12-month survival, with a gradual drop off down to about 60% at about 2 to 2 and a half years,” Moore said. “Overall, terlipressin is a very safe and effective therapy to control variceal bleeding which enables clinicians to buy time in order to initiate more definitive therapy in the form of band ligation. It is for that reason that terlipressin remains the main treatment of stay in the United Kingdom.”
Collapse
Moore K, et al. Real-world Treatment Patterns and Outcomes in Patients with Esophageal Variceal Hemorrhage and
Liver Cirrhosis in United Kingdom: A Retrospective Chart Review Study. Presented at: ACG Annual Scientific Meeting; Oct. 22-27, 2021; Las Vegas (hybrid meeting).
Read more about
Click Here to Manage Email Alerts